GlaxoSmithKline is considering a stg£36-billion bid for Eli Lilly to form a drugs giant valued at more than £100 billion, according to media reports.
GlaxoSmithKline is considering a stg£36-billion bid for Eli Lilly to form a drugs giant valued at more than £100 billion, according to media reports.
Eli Lilly is understood to be Glaxo's leading target among other candidates such as Bristol Myers Squibb, Schering Plough and Roche Holdings.
A spokesman for Glaxo said: "Our strategy is to mature the business and build up the product pipeline. But if a value enhancing deal should become available then we are ready to look at it."
